NCT03254901 is a clinical trial of Screening test by Oraquick test in Hepatitis C, sponsored by Assiut University.

Who is sponsoring NCT03254901?

NCT03254901 is sponsored by Assiut University.

What drugs are being tested in NCT03254901?

Interventions in NCT03254901: Screening test by Oraquick test.

What condition does NCT03254901 study?

NCT03254901 studies Hepatitis C.

Is NCT03254901 still recruiting?

NCT03254901 is currently status unknown. Last updated 21 August 2017.

Last reviewed 2017-08-21 · How we verify

NCT03254901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Detection of Hepatitis C Infection by Oraquick Test Among Health Care Workers

Status unknown Last updated 21 August 2017

What this trial tests

trial testing Screening test by Oraquick test in Hepatitis C in 1,200 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 June 2018

1 July 2018

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,200
Start date	1 January 2018
Primary completion	1 June 2018
Estimated completion	1 July 2018
Sites	1 location across Egypt

Drugs / interventions tested

Screening test by Oraquick test

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Assiut University

Who can join

Adults 21 to 59, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Viral hepatitis is a global health problem affecting hundred millions of people worldwide and considered the main cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation in developing countries.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03254901 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 21 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03254901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing